

Contents

	CFTR and cystic fibrosis	13
1.1.	To set the stage: Cystic Fibrosis – etiology and significance	13
1.2.	The Molecular Structures of CFTR	13
1.2.1.	CFTR is an unusual ABC transporter and an unusual ion channel	14
1.2.2.	Structure of the non-phosphorylated CFTR	15
1.2.3.	Structure of phosphorylated CFTR in complex with ATP	16
1.2.4.	Conformational changes leading to channel opening	16
1.2.5.	The TM hinge as a hotspot for CFTR potentiation	17
1.3.	Features of CFTR: an epithelial anion channel with complex regulation	19
1.3.1.	The functional architecture of CFTR	19
1.3.2.	Phosphorylation-dependent regulation of CFTR: the RD	19
1.3.3.	Regulation of CFTR channel gating by ATP binding and hydrolysis: the NBDs	20
1.3.4.	Anion flow through the CFTR pore: the MSDs	21
1.3.5.	Structural rearrangements of CFTR domains during channel gating	22
1.4.	Basic defect in cystic fibrosis	23
1.4.1.	CF mutations cause molecular defects in the CFTR Cl ⁻ channel	24
1.4.2.	CF-associated mutations cause deficits of CFTR function	25
1.4.3.	Functional deficits of CFTR mutants lead to defects in epithelial function	25
1.4.4.	CFTR dysfunction causes defects in non-epithelial tissues	26
1.5.	Population genetics of <i>CFTR</i> mutations	26
1.6.	Molecular pathology of <i>CFTR</i> mutations	33
1.6.1.	Deletions, frame-shift mutations and stop mutations	33
1.6.2.	Splice mutations	34
1.6.3.	Missense mutations	34
1.6.4.	The major mutation p.Phe508del	34
1.7.	References	35
	Bioassays to assess CFTR function in humans	43
2.1.	Sweat chloride test and β -adrenergic sweat secretion	43
2.2.	Nasal transepithelial potential difference measurements	45
2.2.1.	Background	45
2.2.2.	Principle of the assay	45
2.2.3.	Applications	46
2.3.	Intestinal current measurements	47
2.3.1.	Principle of the assay	47
2.3.2.	Applications	48
2.4.	Primary cystic fibrosis intestinal organoids	51
2.4.1.	What are organoids?	51
2.4.2.	Organoid swelling as measure of transepithelial ion transport	51
2.4.3.	Exploring organoids as living biomarker	54
2.5.	Immunochemical CFTR protein analysis in patients' tissues	55
2.6.	References	56

	Endpoints of phase II and phase III trials with CFTR modulators	65
3.1.	Lung function	65
3.2.	Imaging	66
3.3.	Extra-pulmonary endpoints	69
3.4.	References	71
	Correctors of nonsense mutations: Molecular principles, preclinical and clinical trials	77
4.1.	Read-through of premature termination codons	77
4.2.	Novel drug developments	78
4.3.	The role of CFTR modulators as a therapeutic approach for <i>CFTR</i> nonsense mutations	79
4.4.	Variability in the response to read-through treatment	80
4.5.	NMD as a regulator of the response to read-through treatment	80
4.6.	UPR as a regulator of the response to read-through treatment	81
4.7.	References	83
	CFTR correctors and CFTR potentiators	89
5.1.	Preclinical studies	89
5.2.	Clinical pharmacology: Pharmacokinetics, metabolism and drug-drug interactions	92
5.2.1.	Polypharmacy and Cystic Fibrosis	92
5.2.2.	Comparison of the CFTR modulators	93
5.2.3.	Pharmacokinetics of the CFTR modulators	93
5.2.3.1.	Distribution	93
5.2.3.2.	Metabolism	94
5.2.4.	Impact of Cyp-inhibitors on ivacaftor serum levels	94
5.2.5.	Impact of liver function	94
5.2.6.	Inducers of the Cyp-System	95
5.2.7.	Tezacaftor and elexacaftor – novel agents with lower risk for interactions	95
5.3.	Clinical trials	96
5.4.	Post-approval studies	104
5.5.	References	107
	Perspectives on mutation-specific drug therapies for cystic fibrosis	121
6.1.	References	124
	Abbreviations	127
	Index	128